Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Targeted Search
Clinical Trials Search Results
Query: "AREA[SponsorSearch](AOP Orphan Pharmaceuticals AG)"
Count: 14
Selected: 0
| NCT ID | Title |
|---|
| NCT02523638 | Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients | ||
| NCT02218047 | AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. | ||
| NCT02076815 | Anagrelide Retard in Essential Thrombocythemia | ||
| NCT01949805 | Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera | ||
| NCT01741519 | Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers | ||
| NCT01652898 | A Pharmacokinetic, Pharmacodynamic, Safety Study With AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers | ||
| NCT01313143 | A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol | ||
| NCT01230775 | Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia | ||
| NCT01193699 | Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera | ||
| NCT01065038 | Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia | ||
| NCT00671736 | Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis | ||
| NCT03003325 | The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV | ||
| NCT01933906 | Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response | ||
| NCT03117816 | ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission |
